Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00432276 · ClinicalTrials.gov registry record · Phase 3
Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus
A Phase 3 study of Diabetes Mellitus, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 803
- Enrollment target
- 20
- Study locations
NCT00432276: Completed Phase 3 study of Diabetes Mellitus, sponsored by Takeda.
NCT00432276 is a Phase 3 study of Diabetes Mellitus that has completed, run by Takeda. The registered enrollment target is 803 participants, below the 1,864-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (57% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00432276, a Phase 3 study of Diabetes Mellitus, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 803 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to compare the effect of adding alogliptin, once daily (QD), to the ongoing treatment regimen of pioglitazone HCl and metformin in patients with inadequate glycemic control.
Primary Outcome
The change from Baseline to Week 26 and Week 52 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Metformin
- DRUG Pioglitazone
- DRUG Alogliptin
Study Locations (20)
Florida
- - Clearwater
- - Hialeah
- - Lakeland
- - Marianna
- - Miami
- - North Miami Beach
- - Pembroke Pines
- - Sebastian
- - South Miami
- - Tampa
California
- - Foothill Ranch
- - Los Alamitos
- - Los Angeles
- - Pismo Beach
- - San Diego
Alabama
- - Birmingham
- - Huntsville
Arizona
- - Lake Havasu City
Arkansas
- - Little Rock
Colorado
- - Golden
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 803 participants |
| Start Date | 2007-01 |
| Est. Completion | 2009-06 |
| Phase | Phase 3 |
What the finished NCT00432276 record still lists
NCT00432276 is an interventional study that assigns participants to a tested intervention. The registered 803 participants enrollment target is mid-sized for trials with a published cap, below the 1,864-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (57% lower).
The record links to 1 condition, with Diabetes Mellitus appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT00432276 names 20 study sites across 6 states, led by Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT00432276 about?
NCT00432276 is a clinical study titled "Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus". The purpose of the study is to compare the effect of adding alogliptin, once daily (QD), to the ongoing treatment regimen of pioglitazone HCl and metformin in patients with inadequate glycemic control.
What is the current status of trial NCT00432276?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 803 participants. The study started on 2007-01. Estimated completion is 2009-06.
What conditions does trial NCT00432276 study?
This clinical trial studies the following conditions: Diabetes Mellitus.
What interventions are being tested in trial NCT00432276?
The interventions under investigation include: Placebo (DRUG), Metformin (DRUG), Pioglitazone (DRUG), Alogliptin (DRUG).
Who is sponsoring clinical trial NCT00432276?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00432276 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00432276's enrollment target sits among peer trials
803 29th of 208 higher than 180 of 208 other Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer
RECRUITING · Phase 3
-
Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)
RECRUITING · Phase 3
-
Effect of a Decision Aid About Statin Use in Patients With Type 2 Diabetes Mellitus
COMPLETED · Phase 3
-
Compare Blood Sugar Level Between Lantus in the Morning and Other Insulins in Type 1 Diabetes Adolescents
COMPLETED · Phase 3
-
Treatment of Peripheral Neuropathy in Patients With Diabetes
COMPLETED · Phase 3
-
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04423211 · 804 participants · Phase 3
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
- NCT06522022 · 804 participants · NA
PTSD Screening in Pregnant Black Women
- NCT03524430 · 801 participants · NA
RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy
- NCT04613596 · 806 participants · Phase 2
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia